At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 743 enrolled
Drug / intervention
Bimekizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Bimekizumab, Secukinumab, and 1 other intervention for Chronic Plaque Psoriasis and Moderate to Severe Chronic Plaque Psoriasis. Completed, enrolled 743 participants across 77 sites in 11 countries.
Detailed Summary
This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Belgium, Canada, France, Germany, Netherlands, Poland, Spain, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartJun 2018
Primary CompletionSep 2019
Study CompletionAug 2023
TodayJul 2026
First PostedMay 25, 2018
Enrollment StartJun 13, 2018
Primary CompletionSep 12, 2019
Study CompletionAug 9, 2023
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.1 years ago
Interventions
Bimekizumabdrug
Subjects will receive bimekizumab at pre-specified time-points.
Secukinumabdrug
Subjects will receive secukinumab at pre-specified time-points.
Placeboother
Subjects will receive placebo at pre-specified time-points to maintain the blinding in the double-blind Treatment Period.